Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole story

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug program. But for Valneva CEO Thomas Lingelbach, the regulatory future of the Pfizer-partner Lyme disease vaccine, VLA15, is very much “a matter of negotiation.” The recent phase 3 trial results for VLA15, which failed to meet its primary efficacy endpoint, have raised concerns about the vaccine's prospects. However, Lingelbach is optimistic, arguing that the situation is not as dire as it initially appears.

The phase 3 trial, conducted in Europe, aimed to assess the vaccine's ability to prevent Lyme disease in adults. The primary endpoint was the reduction in the risk of Lyme disease infection by at least 70% compared to the placebo group. While the results did not meet this threshold, the vaccine still showed a significant reduction in the risk of disease, albeit at a lower rate. This discrepancy has led to questions about the vaccine's efficacy and its potential approval by regulatory bodies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Lingelbach acknowledges the challenge posed by the missed primary endpoint but emphasizes that the trial's secondary endpoints provided valuable insights. The vaccine demonstrated a 36% reduction in the risk of Lyme disease, which, while not sufficient for the primary endpoint, is still a meaningful improvement over the placebo group. Additionally, the vaccine showed a higher efficacy rate in certain subgroups, such as those infected with specific strains of the Borrelia burgdorferi bacteria. These findings suggest that the vaccine may be more effective in targeted populations, a point that could be further explored in future studies.

Another factor to consider is the complexity of Lyme disease itself. The disease is caused by multiple strains of bacteria and can manifest in various forms, making it difficult to design a vaccine that covers all possibilities. Valneva's VLA15 targets a specific strain, and while it may not be universally effective, it could still provide significant protection against that particular strain. This targeted approach might be more practical than a one-size-fits-all solution, especially given the diverse nature of Lyme disease.

Furthermore, the partnership between Valneva and Pfizer could play a crucial role in shaping the vaccine's regulatory path. Pfizer, with its extensive regulatory experience and resources, can help navigate the complex process of getting the vaccine approved. The company's involvement could also bolster public confidence in the vaccine, as it brings credibility and additional expertise to the table.

Lingelbach also points out that the missed primary endpoint does not necessarily mean the end of the road for VLA15. Regulatory agencies often consider a range of factors when evaluating a vaccine's potential benefits and risks. In this case, the secondary endpoints, the vaccine's efficacy in specific subgroups, and the overall need for a Lyme disease vaccine could all be taken into account. The EMA and FDA may be more flexible in their assessment, recognizing that the vaccine still offers a meaningful reduction in disease risk and could be an important tool in managing Lyme disease.

Moreover, Valneva is not sitting idle while awaiting regulatory decisions. The company is already working on a next-generation vaccine, VLA20, which targets a broader range of Borrelia burgdorferi strains. This updated formulation could potentially address the limitations of VLA15 and offer even greater efficacy. By continuing to innovate and refine their approach, Valneva aims to ensure that a successful Lyme disease vaccine is eventually available to patients.

In conclusion, while the missed primary endpoint in the phase 3 trial for Valneva's Pfizer-partnered Lyme disease vaccine, VLA15, has raised concerns, it does not tell the entire story. The secondary endpoints, the vaccine's efficacy in specific subgroups, and the potential for regulatory flexibility all point to a more nuanced situation than initially apparent. With Pfizer's support and Valneva's commitment to further development, the future of VLA15 and its successor remains a matter of negotiation and careful consideration by regulatory bodies. The ultimate goal—providing patients with a viable option to prevent Lyme disease—remains within reach, albeit with a complex and uncertain path ahead.